Caribou Biosciences Inc.

Brief Description

Caribou was founded to drive the commercialization of applications based on the remarkable nucleic acid modification capabilities found in prokaryotic CRISPR systems. These were characterized as a form of prokaryotic adaptive immunity that provides a critical line of defense against invading phages, plasmids, and environmental nucleic acids. CRISPR systems have evolved to enable prokaryotes to acquire DNA from their environment and incorporate it into their genomes within specialized arrays of repetitive DNA. These CRISPR sequences act as genomic memory that can be accessed to defend the cell when it is invaded by plasmids or phages that contain the recorded sequences.


Tech Category

  • Research Tools